FDA needs more information on Osteoport:
This article was originally published in Clinica
Executive Summary
LifeQuest Medical says the US FDA requires additional information in order to complete its review of the Osteoport PMA application. Clarifications and further analysis of existing data, as well as additional patient trials, may be necessary for the intraosseous infusion device.